Application of teprenone in preparation of medicine for preventing and treating fatty liver/steatohepatitis

Abstract

The invention discloses teprenone (the other name is pentatetraterpenone, and the chemical name is 6,10,14,18-tetramethyl-5,9,13,17-nonadecatetraterpene-2-one). The invention also relates to application of the compound in preparation of medicines for preventing and treating fatty liver / steatohepatitis. In addition to being prepared into capsules, the compound can also be prepared into tablets, powder, granules, oral liquid, injection and other medicine forms. In-vitro test results show that after FL83b cells of an in-vitro fatty degeneration model are stimulated by GGA for 24 hours, lipid droplets in the cells are obviously reduced; and animal experiment results are as follows: 12 weeks after continuous administration of 200mg / kg of GGA to a mouse with fatty liver induced by high fat-cholesterol-fructose diet, the weight gain of the mouse with high fat diet is reduced; meanwhile, the level of serum alanine aminotransferase is remarkably reduced, and the level of cholesterol is remarkably reduced; in addition, inflammation in liver tissues is remarkably relieved, and the fatty degeneration area is remarkably reduced; the serum insulin level is obviously reduced, and the insulin resistance is obviously improved. The medicine is remarkable in curative effect, high in safety, low in price and capable of relieving the economic burden of patients.

Description

technical field [0001] The invention relates to a new application of a compound, in particular to the application of teprenone in the preparation of drugs for the prevention and treatment of fatty liver / steatohepatitis. Background technique [0002] Fatty liver, (called non-alcoholic fatty liver in the past, and now also called metabolism-related fatty liver) is the most common health problem in the world at present, and its incidence rate is increasing year by year. It is estimated that the global prevalence rate reaches 25%. It has become the main cause of liver-related cardiovascular disease morbidity and death. Numerous studies have clearly shown that fatty liver is a metabolic disease and a hepatic manifestation of a systemic metabolic disorder. The 2020 international expert consensus suggests that non-alcoholic fatty liver disease be renamed metabolism-related fatty liver disease. In order to make the appellation consistent, it is uniformly referred to as "fatty live...

AI Technical Summary

Problems solved by technology

Despite the rapid development of drug research and development and clinical trials, due to the short duration of drug clinical trials, and the safety and effectiveness of long-term medication needs to be further clarified, there is still no approved drug for the treatment of fatty liver

Images